PODAGRA ZAMONAVIY DIAGNOSTIKA VA DAVOLASH YONDASHUVLARI KLINIK-AMALIY AHAMIYATI
Keywords:
podagra, giperurikemiya, siydik kislotasi, urat kristallari, diagnostika, ultratovush, dual-energetik KT, allopurinol, febuksostat.Abstract
Podagra purin almashinuvi buzilishi natijasida yuzaga keladigan va organizmda siydik kislotasi miqdorining ortishi bilan tavsiflanadigan surunkali metabolik kasallik hisoblanadi. Kasallikning asosiy patogenetik mexanizmi giperurikemiya fonida monosodiy urat kristallarining bo‘g‘imlar, periartikulyar to‘qimalar hamda ayrim ichki organlarda to‘planishi bilan bog‘liq. So‘nggi o‘n yilliklarda dunyo miqyosida podagra bilan kasallanish ko‘rsatkichlarining ortib borishi ushbu patologiyani nafaqat revmatologik, balki muhim tibbiy-ijtimoiy muammo sifatida ham ko‘rib chiqishni talab qilmoqda. Epidemiologik kuzatuvlar natijalariga ko‘ra, rivojlangan davlatlarda katta yoshdagi aholi orasida podagra tarqalishi 1–4 % ni tashkil etadi. Erkaklarda kasallik ayollarga nisbatan bir necha barobar ko‘proq uchraydi va yosh ortishi bilan uning rivojlanish xavfi sezilarli darajada oshadi. Mazkur maqolada podagraning zamonaviy diagnostik mezonlari, kasallikning klinik namoyon bo‘lish xususiyatlari, laborator va instrumental tekshiruv usullarining diagnostik ahamiyati hamda davolashning yangi yondashuvlari ilmiy adabiyotlar asosida tahlil qilindi. Shuningdek, uratni pasaytiruvchi terapiya, yallig‘lanishga qarshi davolash usullari, biologik preparatlar va bemorlarni uzoq muddatli kuzatish strategiyalarining samaradorligi baholandi. Tadqiqotlar natijalari podagrani erta aniqlash, individual davolash rejasini ishlab chiqish hamda hayot tarzini modifikatsiya qilish kasallik nazoratini yaxshilashda muhim omil ekanligini ko‘rsatdi.
References
1. Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021). Gout. The Lancet, 397(10287), 1843–1855.
2. FitzGerald, J. D., Dalbeth, N., Mikuls, T., et al. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744–760.
3. Richette, P., Doherty, M., Pascual, E., et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76(1), 29–42.
4. Bardin, T., & Richette, P. (2017). Definition of hyperuricemia and gouty conditions. Current Opinion in Rheumatology, 29(2), 113–119.
5. Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2016). Gout. The Lancet, 388(10055), 2039–2052.
6. Neogi, T. (2018). Clinical practice: Gout. New England Journal of Medicine, 378(5), 443–452.
7. Ragab, G., Elshahaly, M., & Bardin, T. (2017). Gout: An old disease in new perspective. Journal of Advanced Research, 8(5), 495–511.
8. Stamp, L. K., & Dalbeth, N. (2019). Improving outcomes in gout. Expert Review of Clinical Immunology, 15(10), 1015–1024.
9. Choi, H. K., & Curhan, G. (2018). Independent impact of gout on mortality and cardiovascular risk. Circulation, 138(11), 1112–1121.
10. Kuo, C. F., Grainge, M. J., Zhang, W., & Doherty, M. (2015). Global epidemiology of gout. Nature Reviews Rheumatology, 11(11), 649–662.
11. Pascual, E., Addadi, L., Andrés, M., et al. (2015). Mechanisms of crystal formation in gout. Nature Reviews Rheumatology, 11(12), 725–730.
12. Terkeltaub, R. (2017). Update on gout: New therapeutic strategies. Arthritis Research & Therapy, 19(1), 15–22.
13. Becker, M. A., Schumacher, H. R., Wortmann, R. L., et al. (2015). Febuxostat compared with allopurinol. New England Journal of Medicine, 353(23), 2450–2461.
14. Perez-Ruiz, F., Moreno-Lledó, A., & Urresola, A. (2019). Imaging modalities in gout. Rheumatic Disease Clinics of North America, 45(3), 391–403.
15. Khanna, D., Fitzgerald, J. D., Khanna, P. P., et al. (2016). American College of Rheumatology guidelines for gout management. Arthritis Care & Research, 64(10), 1431–1446.
16. So, A., & Martinon, F. (2017). Inflammation in gout. Current Opinion in Rheumatology, 29(2), 145–150.
17. Zhu, Y., Pandya, B. J., & Choi, H. K. (2016). Prevalence of gout and hyperuricemia. Arthritis & Rheumatology, 63(10), 3136–3141.
18. Wright, A. F., Rudan, I., Hastie, N. D., & Campbell, H. (2018). Genetics of gout and hyperuricemia. Nature Reviews Genetics, 11(6), 432–442.
19. Saag, K. G., Khanna, P. P., Koehnke, R., et al. (2022). Contemporary management of gout. Rheumatology International, 42(4), 601–615.
20. Singh, J. A., Cleveland, J. D., & Gaffo, A. (2023). Advances in gout diagnosis and treatment. Current Opinion in Rheumatology, 35(2), 95–103.
21. Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. (2020). Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 80, 1–11.
22. Dehlin, M., Jacobsson, L., & Roddy, E. (2020). Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology, 16(7), 380–390.
23. Chhana, A., & Dalbeth, N. (2015). The gouty tophus: A review. Current Rheumatology Reports, 17(3), 19–27.
24. Edwards, N. L. (2018). The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clinic Journal of Medicine, 85(1), 13–20.
25. Jansen, T. L., Perez-Ruiz, F., Tausche, A. K., & Richette, P. (2017). Gout, hyperuricemia and crystal-associated disease. Best Practice & Research Clinical Rheumatology, 31(5), 623–633.
26. Keenan, R. T. (2021). Limitations of current therapies and new approaches for gout treatment. Current Rheumatology Reports, 23(4), 24–32.
27. Kim, S. C., Neogi, T., Kang, E. H., Liu, J., Desai, R. J., Zhang, M., & Solomon, D. H. (2018). Cardiovascular risks associated with gout and hyperuricemia. Arthritis Care & Research, 70(10), 1523–1530.
28. Lioté, F., Ea, H. K., & Pascual, E. (2019). Monosodium urate crystal-induced inflammation and gout. Rheumatology, 58(1), 1–10.
29. Mackenzie, I. S., Ford, I., Nuki, G., Hallas, J., Hawkey, C. J., Webster, J., & Walters, M. (2020). Long-term cardiovascular safety of febuxostat compared with allopurinol. The Lancet, 396(10264), 1745–1757.
30. McCormick, N., Rai, S. K., Lu, N., Yokose, C., Curhan, G. C., & Choi, H. K. (2022). Trends in gout prevalence and management worldwide. Arthritis & Rheumatology, 74(6), 991–999.
31. Pascart, T., & Richette, P. (2018). Investigational drugs for hyperuricemia and gout. Expert Opinion on Investigational Drugs, 27(4), 337–344.
32. Roddy, E., & Doherty, M. (2017). Gout and lifestyle factors. Rheumatology, 56(1), 17–23.
33. Roughley, M. J., Belcher, J., Mallen, C. D., & Roddy, E. (2015). Gout and risk of chronic kidney disease. Rheumatology, 54(1), 34–39.
34. Singh, J. A., Gaffo, A., & Saag, K. G. (2021). New developments in gout management. The BMJ, 372, n104.
35. Stamp, L. K., Chapman, P. T., Barclay, M. L., & Horne, A. (2017). Emerging therapies in the long-term management of hyperuricemia and gout. Internal Medicine Journal, 47(10), 1133–1140.
36. Tausche, A. K., Jansen, T. L., Schröder, H. E., Bornstein, S. R., Aringer, M., & Müller-Ladner, U. (2019). Gout—Current diagnosis and treatment. Deutsches Ärzteblatt International, 116(49), 843–850.
37. Terkeltaub, R., Bushinsky, D. A., & Becker, M. A. (2016). Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Research & Therapy, 18(1), 1–9.
38. Wortmann, R. L. (2017). Disorders of purine and pyrimidine metabolism. In Harrison's Principles of Internal Medicine (20th ed., pp. 3120–3132). McGraw-Hill Education.
39. Yamanaka, H. (2018). Japanese guideline for the management of hyperuricemia and gout. Nucleosides, Nucleotides and Nucleic Acids, 37(12), 695–703.
40. Zhang, W., Doherty, M., Pascual, E., Barskova, V., Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., McCarthy, G., Netter, P., Nuki, G., Perez-Ruiz, F., Pignone, A., Pimentão, J., Punzi, L., Roddy, E., Uhlig, T., & Zimmermann-Górska, I. (2016). EULAR evidence-based recommendations for gout diagnosis. Annals of the Rheumatic Diseases, 75(3), 499–510.
O‘zbekiston Respublikasi, Andijon viloyati, Shahrixon tumani
(+998) 945668868